Adverum Biotechnologies Stock In The News

ADVM Stock  USD 2.71  0.06  2.17%   
Our overall analysis of Adverum Biotechnologies' news coverage and content from conventional and social sources shows investors' bearish mood towards Adverum Biotechnologies. The specific impact of Adverum Biotechnologies news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Adverum Biotechnologies' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Adverum Biotechnologies headlines in addition to utilizing other, more conventional financial analysis modules. Check out Adverum Biotechnologies Backtesting and Adverum Biotechnologies Hype Analysis.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

Adverum Biotechnologies Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream
https://www.globenewswire.com/news-release/2025/07/16/3116247/0/en/Presenting-on-Emerging-Growth-Conference-84-Day-2-on-July-17-Register-to-live-stream.html
 Bullish
Macroaxis News: globenewswire.com
Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream
https://www.globenewswire.com/news-release/2025/07/15/3115440/0/en/Presenting-on-Emerging-Growth-Conference-84-Day-1-on-July-16-Register-to-live-stream.html
 Bullish
Yahoo News
Wet Age-Related Macular Degeneration (We...
https://finance.yahoo.com/news/wet-age-related-macular-degeneration-084700188.html
 Bullish
Investing News at Macroaxis
Adverum Biotechnologies price target lowered to $12 at Mizuho
https://www.investing.com/news/analyst-ratings/adverum-biotechnologies-price-target-lowered-to-12-at-mizuho-93CH-4111468
 Bullish
Investing News at Macroaxis
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces pivotal year
https://www.investing.com/news/swot-analysis/adverum-biotechnologies-swot-analysis-gene-therapy-stock-faces-pivotal-year-93CH-4095630
 Bullish
Macroaxis News: globenewswire.com
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2025/06/05/3094759/32452/en/Adverum-Biotechnologies-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Bullish
Macroaxis News: globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
https://www.globenewswire.com/news-release/2025/05/05/3074440/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Adverum-Biotechnologies-Inc-ADVM.html
 Neutral
Macroaxis News: globenewswire.com
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2025/05/02/3073526/32452/en/Adverum-Biotechnologies-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Bullish
Macroaxis News: globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
https://www.globenewswire.com/news-release/2025/04/29/3070493/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-on-Behalf-of-Investors-of-Adverum-Biotechnologies-Inc-ADVM.html
 Neutral
Macroaxis News: globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
https://www.globenewswire.com/news-release/2025/04/25/3068529/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-on-Behalf-of-Investors-of-Adverum-Biotechnologies-Inc-ADVM.html
 Neutral

Adverum Biotechnologies Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Adverum and other traded companies coverage with news coverage. We help investors stay connected with Adverum headlines for the 22nd of July to make an informed investment decision based on correlating the impacts of news items on Adverum Stock performance. Please note that trading solely based on the Adverum Biotechnologies hype is not for everyone as timely availability and quick action are needed to avoid losses.
Adverum Biotechnologies' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Adverum Biotechnologies investors visualize upcoming and past events in order to time the market based on Adverum Biotechnologies noise-free hype analysis.

Adverum Biotechnologies Investors Sentiment

The influence of Adverum Biotechnologies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Adverum. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Adverum Biotechnologies' public news can be used to forecast risks associated with an investment in Adverum. The trend in average sentiment can be used to explain how an investor holding Adverum can time the market purely based on public headlines and social activities around Adverum Biotechnologies. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Adverum Biotechnologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Adverum Biotechnologies' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Adverum Biotechnologies' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Adverum Biotechnologies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adverum Biotechnologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adverum Biotechnologies' short interest history, or implied volatility extrapolated from Adverum Biotechnologies options trading.
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:
Check out Adverum Biotechnologies Backtesting and Adverum Biotechnologies Hype Analysis.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.22)
Revenue Per Share
0.048
Quarterly Revenue Growth
(0.70)
Return On Assets
(0.49)
Return On Equity
(1.45)
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.